Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 1,100 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 1,100 shares of the firm’s stock in a transaction on Friday, July 24th. The shares were bought at an average cost of $12.88 per share, for a total transaction of $14,168.00. Following the acquisition, the chief executive officer owned 5,607,702 shares in the company, valued at approximately $72,227,201.76. The trade was a 0.02% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Snehal Patel also recently made the following trade(s):

• On Thursday, July 23rd, Snehal Patel bought 2,500 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $13.14 per share, with a total value of $32,850.00.

Greenwich LifeSciences Trading Up 0.1%

Shares of NASDAQ GLSI opened at $13.45 on Wednesday. Greenwich LifeSciences, Inc. has a 1-year low of $7.78 and a 1-year high of $34.10. The company has a 50-day moving average of $21.63 and a two-hundred day moving average of $24.26. The company has a market cap of $197.45 million, a PE ratio of -8.57 and a beta of 1.40.

Hedge Funds Weigh In On Greenwich LifeSciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Sei Investments Co. acquired a new stake in Greenwich LifeSciences during the 1st quarter worth $627,000. Bank of New York Mellon Corp boosted its position in shares of Greenwich LifeSciences by 235.5% in the 1st quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after purchasing an additional 32,657 shares during the last quarter. Strs Ohio grew its stake in shares of Greenwich LifeSciences by 140.4% during the first quarter. Strs Ohio now owns 13,700 shares of the company’s stock worth $329,000 after purchasing an additional 8,000 shares during the period. Virtu Financial LLC bought a new stake in Greenwich LifeSciences in the fourth quarter valued at about $605,000. Finally, XTX Topco Ltd acquired a new position in Greenwich LifeSciences in the fourth quarter valued at about $217,000. 4.16% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GLSI has been the subject of several research analyst reports. Wall Street Zen cut shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Finally, HC Wainwright upped their price target on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $57.00.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.